Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Offidani

Showing results (41-50 of 149) with videos related to

Pageof 15
Sort By:
Haematologica|March 9, 2004
Mucormycosis in hematologic patientsLivio Pagano, Massimo Offidani, Luana Fianchi, et al.
European Journal of Haematology|February 14, 2004
Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysisAttilio Olivieri, Marino Brunori, Debora Capelli, et al.
Expert Opinion on Investigational Drugs|April 5, 2013
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myelomaMassimo Martino, Attilio Olivieri, Massimo Offidani, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|August 7, 2004
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myelomaMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Blood|February 5, 2008
Thalidomide for treatment of multiple myeloma: 10 years laterAntonio Palumbo, Thierry Facon, Pieter Sonneveld, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study)Livio Pagano, Morena Caira, Massimo Offidani, et al.
European Journal of Haematology|May 7, 2004
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Haematologica|July 21, 2022
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panelValerio De Stefano, Alessandra Larocca, Monica Carpenedo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 13, 2012
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantationVittorio Montefusco, Francesco Spina, Francesca Patriarca, et al.
Expert Opinion on Biological Therapy|July 14, 2012
Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient programMassimo Martino, Mauro Montanari, Benedetto Bruno, et al.
Pageof 15

Showing results (41-50 of 149) with videos related to

Sort By:
Pageof 15
Haematologica|March 9, 2004
Mucormycosis in hematologic patientsLivio Pagano, Massimo Offidani, Luana Fianchi, et al.
European Journal of Haematology|February 14, 2004
Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysisAttilio Olivieri, Marino Brunori, Debora Capelli, et al.
Expert Opinion on Investigational Drugs|April 5, 2013
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myelomaMassimo Martino, Attilio Olivieri, Massimo Offidani, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|August 7, 2004
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myelomaMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Blood|February 5, 2008
Thalidomide for treatment of multiple myeloma: 10 years laterAntonio Palumbo, Thierry Facon, Pieter Sonneveld, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study)Livio Pagano, Morena Caira, Massimo Offidani, et al.
European Journal of Haematology|May 7, 2004
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Haematologica|July 21, 2022
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panelValerio De Stefano, Alessandra Larocca, Monica Carpenedo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 13, 2012
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantationVittorio Montefusco, Francesco Spina, Francesca Patriarca, et al.
Expert Opinion on Biological Therapy|July 14, 2012
Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient programMassimo Martino, Mauro Montanari, Benedetto Bruno, et al.
Pageof 15